Seroatlas · Human Serome Atlas

LDLRAD3

Low-density lipoprotein receptor class A domain-containing protein 3

Also known as: LRAD3, LRAD3_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q86YD5
Gene: LDLRAD3
Ensembl: ENSG00000179241
Chromosome: 11
Canonical length: 345 aa
Protein class: Predicted membrane proteins
Subcellular location: Cell Junctions

OverviewNCBI Gene

Predicted to enable amyloid-beta binding activity. Predicted to be involved in receptor-mediated endocytosis. Predicted to act upstream of or within regulation of protein processing. Predicted to be located in endomembrane system and membrane. Predicted to be active in plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

345 residues, UniProt reviewed canonical sequence.

>Q86YD5|LDLRAD3
     1  MWLLGPLCLL LSSAAESQLL PGNNFTNECN IPGNFMCSNG RCIPGAWQCD GLPDCFDKSD
    61  EKECPKAKSK CGPTFFPCAS GIHCIIGRFR CNGFEDCPDG SDEENCTANP LLCSTARYHC
   121  KNGLCIDKSF ICDGQNNCQD NSDEESCESS QEPGSGQVFV TSENQLVYYP SITYAIIGSS
   181  VIFVLVVALL ALVLHHQRKR NNLMTLPVHR LQHPVLLSRL VVLDHPHHCN VTYNVNNGIQ
   241  YVASQAEQNA SEVGSPPSYS EALLDQRPAW YDLPPPPYSS DTESLNQADL PPYRSRSGSA
   301  NSASSQAASS LLSVEDTSHS PGQPGPQEGT AEPRDSEPSQ GTEEV

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against LDLRAD3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.57
Highest tissue expression: 28 nTPM

Expression across tissuesHPA

Tissue

spinal cord: 28 nTPM
salivary gland: 19 nTPM
cerebellum: 19 nTPM
breast: 17 nTPM
skin: 13 nTPM
ovary: 13 nTPM

Single-cell type

bergmann glia: 479 nCPM
oligodendrocyte progenitor cells: 437 nCPM
salivary acinar cells: 434 nCPM
prostatic glandular cells: 358 nCPM
adipocytes: 353 nCPM
thymic myoid cells: 301 nCPM

Immune cell

non-classical monocyte: 6.5 nTPM
classical monocyte: 4.8 nTPM
intermediate monocyte: 4.6 nTPM
myeloid DC: 3.1 nTPM
total PBMC: 1.8 nTPM
basophil: 1.4 nTPM

Brain region

medulla oblongata: 43 nTPM
cerebellum: 39 nTPM
white matter: 35 nTPM
midbrain: 31 nTPM
pons: 31 nTPM
spinal cord: 29 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.83
gnomAD pLI: 0.02
gnomAD missense Z: 0.7
DepMap mean gene effect: 0.02
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

amyloid-beta binding

Cellular components

plasma membrane

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of LDLRAD3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads LDLRAD3 as an antibody target. Whether an autoantibody or antibody against LDLRAD3 could matter depends on whether native LDLRAD3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

LDLRAD3 is annotated at the cell surface, where native LDLRAD3 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label LDLRAD3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...